Does Florida Blue Cover Ozempic?
The verdict
Conditional on most plans
Florida Blue covers Ozempic for type 2 diabetes with prior authorization — Ozempic appears on Florida Blue's GLP-1 diabetes medication list. Florida Blue has an explicit commercial policy excluding GLP-1s for weight-loss use, effective 2025. The T2D/weight-loss split is binary and documented: on the GLP-1 diabetes list with PA, covered; prescribed for weight management, explicitly denied.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Florida Blue (Blue Cross Blue Shield of Florida) using your member ID.
Key facts
Florida Blue maintains an explicit commercial GLP-1 weight-loss exclusion policy (effective 2025) while retaining Ozempic coverage for type 2 diabetes on a separate GLP-1 diabetes medication list.
Florida Blue GLP-1 commercial policy, 2025
Ozempic is FDA-approved for type 2 diabetes glycemic control, cardiovascular risk reduction in T2D patients with known CVD, and CKD progression in T2D patients — not for weight loss.
FDA drug labeling (semaglutide injection)
The IRA Maximum Fair Price for semaglutide under Medicare is $274 per 30-day supply, effective January 1, 2027 — a 71% discount off the CY2024 list price.
CMS, IRA Drug Price Negotiation Program, 2024
Medicare vs. commercial coverage
Whether Florida Blue (Blue Cross Blue Shield of Florida) covers Ozempic depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Part D (Florida Blue Medicare plans): Ozempic is covered for type 2 diabetes with prior authorization under standard Part D rules. The 2026 Part D out-of-pocket cap is $2,100. Medicare beneficiaries cannot use the NovoCare savings card — federal anti-kickback rules exclude Medicare and Medicaid enrollees. Ozempic is not covered for off-label weight-loss use under Medicare Part D; off-label use is statutorily excluded. The IRA Maximum Fair Price for semaglutide drops to $274 per 30-day supply effective January 1, 2027. Verify tier and cost-share on your specific Florida Blue Medicare plan formulary.
Commercial / Employer
Group & marketplace plans
Commercial/Employer: Ozempic is on Florida Blue's GLP-1 diabetes medication list and is covered for type 2 diabetes with prior authorization per Florida Blue's 2025 GLP-1 commercial PA policy. Florida Blue's explicit GLP-1 weight-loss exclusion — published in its commercial policy effective 2025, which ended Wegovy weight-loss coverage — applies equally to off-label weight-loss use of Ozempic. Not covered for weight management under any commercial plan. Commercially insured T2D patients may be eligible for the NovoCare Ozempic Savings Card ($25/fill, max $150/28-day) — verify at NovoCare.com. ACA/Individual: covered for T2D with PA; GLP-1 weight-loss use excluded. Florida Medicaid: Ozempic is covered for T2D with prior authorization at nominal Medicaid cost-share per Florida Medicaid PDL. Not covered for off-label weight loss. Verify current tier and criteria on the Florida Medicaid PDL.
The 3 boxes you must tick to get approved
Commercial plans that will consider Ozempic require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
0 of 3 requirements selected. Meet all 3 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Ozempic actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
~$1,028/month (Novo Nordisk published pricing, ~$1,027.51 for the 0.25/0.5 mg pen). NovoCare self-pay: ~$199/month intro price (first two fills through December 31, 2026), then ~$349/month (0.25/0.5/1 mg) or ~$499/month (2 mg).
List price with no coverage — before any manufacturer savings card.
With coverage
Commercial/ACA tier and cost-share not publicly confirmed at the specific plan level — verify on Florida Blue drug lookup tool. Medicare Part D: cost-share per tier; $2,100 OOP cap 2026. IRA Maximum Fair Price of $274/30-day for semaglutide effective January 1, 2027 for Medicare patients. Florida Medicaid: $0–$4 nominal for covered T2D use.
Typical monthly copay once prior authorization is approved.
Bridge program
NovoCare Ozempic Savings Card: commercially insured T2D patients may pay as little as $25 per fill (max $150/28-day). Not available to Medicare or Medicaid beneficiaries. Verify eligibility at NovoCare.com.
Reduced copay through the assistance program, where eligible.
All figures are estimates. Tier and cost-share vary by Florida Blue plan type. Confirm exact cost-share on the Florida Blue drug lookup tool or by calling Florida Blue member services.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Use the Florida Blue drug lookup to confirm Ozempic on your plan's GLP-1 diabetes list
Log in at floridablue.com and use the drug lookup tool to confirm Ozempic appears on your specific plan's GLP-1 diabetes medication list. Florida Blue's explicit commercial policy distinguishes drugs on the GLP-1 diabetes list (Ozempic — covered for T2D with PA) from weight-loss GLP-1 coverage (explicitly excluded). Verify tier, PA requirements, and cost-share for your specific Florida Blue plan.
- 2
Have your prescriber initiate PA with T2D documentation
Your prescriber submits the PA under Florida Blue's 2025 GLP-1 commercial PA criteria. Documentation required: type 2 diabetes diagnosis (ICD-10 E11.x), evidence of metformin step therapy (or documented intolerance/contraindication), and the clinical indication (T2D glycemic control or CV/renal risk reduction — not weight management). Weight-management framing will trigger Florida Blue's explicit GLP-1 weight-loss exclusion.
- 3
Check the NovoCare savings card if you have commercial coverage
If you are enrolled in a Florida Blue commercial or ACA plan (not Medicare or Medicaid), you may qualify for the NovoCare Ozempic Savings Card at $25/fill (max $150/28-day). Visit NovoCare.com to confirm eligibility. Medicare and Medicaid enrollees cannot use this card.
Options if Florida Blue (Blue Cross Blue Shield of Florida) won't cover Ozempic
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Rybelsus (oral semaglutide)
Oral semaglutide for type 2 diabetes. Coverage under Florida Blue varies by plan — verify on the Florida Blue drug lookup. Subject to IRA Maximum Fair Price of $274/30-day effective January 1, 2027 for Medicare patients.
Jardiance (empagliflozin)
SGLT-2 inhibitor commonly required as step therapy before GLP-1 PA approval. Often a preferred brand tier on Florida Blue formularies with lower cost-share than Ozempic.
Metformin (generic)
Tier 1 on all Florida Blue formularies at near-zero cost-share. Required step therapy before Ozempic PA approval on Florida Blue commercial plans.
Compounded semaglutide (weight-loss seekers only)
Florida Blue's explicit GLP-1 weight-loss exclusion is documented and consistent — patients seeking semaglutide for weight management will be denied. Compounded semaglutide from $49/mo is available at getcurex.com/cl/glp without Florida Blue authorization. See the offer section below for full disclaimers.
These options are listed for information only — your own clinician decides what is appropriate for you.
Frequently Asked Questions
No. Florida Blue explicitly excludes GLP-1s for weight-loss use under a documented commercial policy effective 2025 — the same policy that ended Wegovy weight-loss coverage for Florida Blue commercial plans. Ozempic holds no FDA approval for weight loss; it is covered only when prescribed for type 2 diabetes. This exclusion is not a vague formulary omission; it is an explicitly named Florida Blue commercial policy. Weight-loss seekers will be denied under all Florida Blue lines of business.
Florida Blue maintains a named GLP-1 diabetes medication list that identifies GLP-1 receptor agonists covered for type 2 diabetes management with prior authorization. Ozempic (semaglutide) appears on this diabetes list. This list is distinct from the weight-loss GLP-1 exclusion policy — which eliminates commercial coverage of GLP-1s for obesity treatment. The diabetes list is the mechanism by which Florida Blue continues to cover Ozempic for T2D even as it excludes the same drug class for weight loss. Verify the current list via the Florida Blue drug lookup tool.
Florida Blue publicly cited unsustainable cost growth as the reason for ending commercial weight-loss GLP-1 coverage effective 2025. Multiple large BCBS affiliates made similar moves in 2024–2025 (BCBS of Massachusetts, BCBS of Michigan, Independence Blue Cross) for the same reason. Florida Blue's published GLP-1 commercial policy explicitly excludes weight-loss coverage while retaining T2D coverage — a deliberate, transparent policy choice distinguishing on-label diabetes use from off-label or weight-loss-specific use.
Yes, if you are enrolled in a Florida Blue commercial or ACA plan (not Medicare or Medicaid). The NovoCare Ozempic Savings Card offers commercially insured T2D patients as little as $25 per fill (max $150 per 28-day supply). Florida Blue's commercial enrollment makes this card relevant for many Florida Blue members. Verify eligibility at NovoCare.com. Medicare and Medicaid beneficiaries are excluded by federal anti-kickback rules.
The coverage outcomes are nearly opposite. Ozempic for type 2 diabetes: covered with PA under Florida Blue's GLP-1 diabetes medication list. Wegovy for weight loss: explicitly excluded under Florida Blue's commercial GLP-1 weight-loss exclusion policy effective 2025 (Wegovy weight-loss coverage ended). The only weight-loss GLP-1 access for Florida Blue Medicare members is the Medicare GLP-1 Bridge ($50/month, Wegovy for CV indication), which operates outside Part D. This T2D/weight-loss binary is the most clearly documented in the Ozempic insurer cluster.
Related Articles
Does BCBS Michigan Cover Contrave? 2026 MI Guide | Curex
BCBS Michigan upheld weight-loss exclusions (DIFS 2025). Contrave is plan-dependent. MI Medicaid favors weight-loss GLP-1s; Contrave varies by PDL.
Read moreDoes BCBS of Illinois Cover Jardiance? 2026
BCBS of Illinois (HCSC) covers Jardiance across commercial, ACA, Medicare, and Medicaid. Metformin-first step is common. 2026 MFP $197 for Medicare.
Read moreDoes BCBS Alabama Cover Wegovy? 2026 Guide | Curex
BCBS Alabama Wegovy coverage is employer-dependent and unpublished. Alabama Medicaid excludes obesity GLP-1s. How to verify your specific plan.
Read moreDoes Florida Blue Cover Dupixent? 2026 Coverage Guide
Florida Blue covers Dupixent on the specialty tier via Prime Therapeutics with PA and step therapy. Coinsurance 25-33%; $2,100 Part D cap applies.
Read moreDoes Florida Blue Cover Wegovy? 2026 Guide | Curex
Florida Blue excludes Wegovy for weight loss on commercial plans. Only the CV indication is covered. Cash and Medicare Bridge options explained.
Read moreDoes Florida Blue Cover Mounjaro? PA Rules 2026 | Curex
Florida Blue covers Mounjaro for type 2 diabetes with PA via Prime Therapeutics' 2025 GLP-1 rule. Not covered for weight loss. FL Medicaid diabetes-only.
Read moreInsurance won't cover Ozempic for weight loss — here's a path that doesn't need it
You just saw how tangled Ozempic coverage can get — auto-rejections, prior authorization, and high cash prices. Curex compounded semaglutide: $199/month equivalent prepaid annually ($2,388 upfront), or $299/month paid monthly. Compounded tirzepatide: $299/month equivalent prepaid annually ($3,588 upfront), or $399/month paid monthly. Commercial rates as of 2026-10-12; compounded products are not FDA-approved and clinical eligibility must be assessed. Curex compounded medications are not the same as Ozempic. No insurance or prior authorization required; prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Ozempic and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Florida Blue (Blue Cross Blue Shield of Florida) before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Ozempic and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.